Users area
Facts and Trends Analysis 2007
Browse recent years:
Facts and trends 2007 puzzle homepage


The aim of this publication is to provide a comprehensive and incisive picture of the Italian biotech sector in the global context useful for investors, public and private decision makers as well as all parties eager to gain insight in Italy’s life sciences industry. The annual “Facts and Trends Analysis”, integrates www.biodirectory.it, a portal providing continuously updated information and news on Italian biotech. Moreover, www.biodirectory.it contains the profiles of hundreds of organizations based in Italy and active in the biotech sector as well as product and technology descriptions and has become a major gateway to a clear understanding of the Italian biotech industry. With information on the website together with the “Facts & Trends Analysis”, the Italian Biotechnology Directory describes the strengths and the challenges laying ahead for the Italian biotech community effectively placing it in the global playground.
The global overview of the biotech industry has highlighted that the pharmaceutical and biotech companies are considering strategic partnering and M&A as viable strategies to maximize their probability of success. This scenario opens interesting perspectives for the Italian biotech industry, which has proved capable of compensating the lack of a mature investment system with strategic alliances to finance its companies created thanks to strong scientific research. 2006 has been a very important year for the Italian biotech industry thanks to the successful IPOs of Gentium, BioXell and Newron Pharmaceuticals. This 2007 edition of the report highlights also the growth of the four main Italian clusters indicating the strong points of each and their potential complementation.
The analysis shows that these four Italian biotech clusters located in Lombardy, Piedmont, Tuscany and Friuli Venezia- Giulia, have succeeded in weaving an efficient network between SMEs, research organisations, trade associations and local governments creating a favourable milieu for start-up creation and development. The challenge now is to strengthen the clusters and make them grow to into established businesses. Finally, this analysis aims to provide new elements for defining actions and strategies to support the expansion of Italy’s biotech sector. A strong integration among these clusters may create a new development model that could become a reference point at the national level to fill the competitive gap Italy faces in the biotech industry.

Download 2007 report.
Acrobat Pdf File, 5,6 Mbytes.


[Global Overview]

Mar, 04, 2007 Partnering and m&a are the keys for the future development of the sector

Mar, 02, 2007 Interview with Margaret Beer, Merck & Co.

Mar, 04, 2007 Written by Francesco Gulli, Managing Director, Novartis vaccines and diagnostics Italia

    


[Italian Biotech Industry]

Mar, 04, 2007 Written by Roberto Gradnik, President of Assobiotec - Senior Executive Vice President Merck Serono International, Commercial Europe.

Mar, 04, 2007 Interview with Laura Ferro, CEO of Gentium S.p.A.

Mar, 04, 2007 Interview with Francesco Sinigaglia, CEO of BioXell S.p.A.

Mar, 04, 2007 Interview with Luca Benatti, CEO of Newron Pharmaceuticals S.p.A.


[Italian Bioclusters]

Mar, 04, 2007 Critical factors for success.

Mar, 04, 2007 Bioclusters are leading the scene of Life Sciences

Mar, 04, 2007 Developing a market oriented for research and innovation

Mar, 04, 2007 The new "new thing" for knowledge valorization

Mar, 04, 2007